A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Conditions
Melanoma · Clear-Cell Renal-Cell Carcinoma (ccRCC) · Advanced Solid Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California San Francisco (UCSF), San Francisco, California, United States
Yale School of Medicine, North Haven, Connecticut, United States
University of Chicago, Chicago, Illinois, United States
Start Midwest Cancer Research, Grand Rapids, Michigan, United States
Northwell Health, Lake Success, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Next Oncology, San Antonio, Texas, United States
The Start Center for Cancer Care, San Antonio, Texas, United States
Study leads
Clinical Trial Management
Study Director
Regeneron Pharmaceuticals